vs
Side-by-side financial comparison of Eastern Bankshares, Inc. (EBC) and Bio-Techne (TECH). Click either name above to swap in a different company.
Eastern Bankshares, Inc. is the larger business by last-quarter revenue ($295.9M vs $295.9M, roughly 1.0× Bio-Techne). Eastern Bankshares, Inc. runs the higher net margin — 22.1% vs 12.8%, a 9.2% gap on every dollar of revenue. On growth, Eastern Bankshares, Inc. posted the faster year-over-year revenue change (710.6% vs -6.4%). Over the past eight quarters, Eastern Bankshares, Inc.'s revenue compounded faster (38.6% CAGR vs 4.2%).
Eastern Bank is a bank based in Boston, Massachusetts. Before de-mutualizing in 2020, it was the oldest and largest mutual bank in the United States and the largest community bank in Massachusetts.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
EBC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $295.9M | $295.9M |
| Net Profit | $65.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 22.1% | 12.8% |
| Revenue YoY | 710.6% | -6.4% |
| Net Profit YoY | -34.4% | 68.3% |
| EPS (diluted) | $0.29 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $295.9M | — | ||
| Q4 25 | $37.5M | $295.9M | ||
| Q3 25 | $241.5M | — | ||
| Q2 25 | $244.9M | $317.0M | ||
| Q1 25 | $31.1M | $316.2M | ||
| Q4 24 | $216.5M | $297.0M | ||
| Q3 24 | $203.4M | $289.5M | ||
| Q2 24 | $154.0M | $306.1M |
| Q1 26 | $65.3M | — | ||
| Q4 25 | $99.5M | $38.0M | ||
| Q3 25 | $106.1M | — | ||
| Q2 25 | $100.2M | $-17.7M | ||
| Q1 25 | $-217.7M | $22.6M | ||
| Q4 24 | $60.8M | $34.9M | ||
| Q3 24 | $-6.2M | $33.6M | ||
| Q2 24 | $26.3M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | 38.9% | — | ||
| Q2 25 | 41.0% | -7.5% | ||
| Q1 25 | -590.9% | 12.2% | ||
| Q4 24 | 33.3% | 16.0% | ||
| Q3 24 | -1.6% | 13.8% | ||
| Q2 24 | 24.7% | 15.0% |
| Q1 26 | 22.1% | — | ||
| Q4 25 | 265.6% | 12.8% | ||
| Q3 25 | 44.0% | — | ||
| Q2 25 | 40.9% | -5.6% | ||
| Q1 25 | -699.2% | 7.1% | ||
| Q4 24 | 28.1% | 11.7% | ||
| Q3 24 | -3.0% | 11.6% | ||
| Q2 24 | 17.1% | 13.3% |
| Q1 26 | $0.29 | — | ||
| Q4 25 | $0.48 | $0.24 | ||
| Q3 25 | $0.53 | — | ||
| Q2 25 | $0.50 | $-0.11 | ||
| Q1 25 | $-1.08 | $0.14 | ||
| Q4 24 | $0.29 | $0.22 | ||
| Q3 24 | $-0.03 | $0.21 | ||
| Q2 24 | $0.16 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $551.7M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $4.3B | $2.0B |
| Total Assets | $30.6B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $551.7M | — | ||
| Q4 25 | $507.6M | $172.9M | ||
| Q3 25 | $703.4M | — | ||
| Q2 25 | $948.3M | $162.2M | ||
| Q1 25 | $609.0M | $140.7M | ||
| Q4 24 | $1.9B | $177.5M | ||
| Q3 24 | $1.7B | $187.5M | ||
| Q2 24 | $1.4B | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $2.0B | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $3.7B | $1.9B | ||
| Q1 25 | $3.6B | $2.0B | ||
| Q4 24 | $3.6B | $2.1B | ||
| Q3 24 | $3.7B | $2.1B | ||
| Q2 24 | $3.0B | $2.1B |
| Q1 26 | $30.6B | — | ||
| Q4 25 | $30.6B | $2.5B | ||
| Q3 25 | $25.5B | — | ||
| Q2 25 | $25.5B | $2.6B | ||
| Q1 25 | $25.0B | $2.6B | ||
| Q4 24 | $25.6B | $2.7B | ||
| Q3 24 | $25.5B | $2.7B | ||
| Q2 24 | $21.0B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EBC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
